Intra Cellular Therapies reported $-55629000 in Operating Profit for its third fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Profit Change
Acadia Pharmaceuticals ACAD:US USD -30866000 2.78M
ALKERMES ALKS:US USD -60641000 26.18M
Aptinyx Inc APTX:US USD -14657000 2.45M
Biocryst Pharmaceuticals BCRX:US USD -17445000 17.28M
Biogen BIIB:US USD 1.32B 1.37B
Bristol Myers Squibb BMY:US USD 1.94B 528M
Cytokinetics CYTK:US USD -130687000 119.81M
Esperion Therapeutics ESPR:US USD -41623000 10.75M
Gilead Sciences GILD:US USD 2.27B 570M
Halozyme Therapeutics HALO:US USD 80.58M 46.52M
Intra Cellular Therapies ITCI:US USD -55629000 32.29M
Johnson & Johnson JNJ:US USD 4.2B 1.62B
Marinus Pharmaceuticals MRNS:US USD -30099000 6.67M
Minerva Neurosciences NERV:US USD -5207000 1.76M
Nektar Therapeutics NKTR:US USD -54301000 98.54M
Novartis NVS:US USD 1.95B 219M
Prothena PRTA:US USD -50332000 7.12M
Supernus Pharmaceuticals SUPN:US USD -1523000 12.87M
United Therapeutics UTHR:US USD 314.3M 112.5M
Vanda Pharmaceuticals VNDA:US USD 3.91M 447K